The FDA has launched a pilot program for real-time clinical trials, with AstraZeneca and Amgen participating. The program aims to facilitate real-time review of clinical trial data, potentially speeding up the drug review process. The effort may utilize technologies such as artificial intelligence and cloud computing, although details of the program's specifics are not entirely clear.